Von Hippel-Lindau disease (VHL): monitoring
Evidence-based neurology checklist on von hippel-lindau disease (vhl): monitoring: Annual monitoring History and physical examination Pulse and blood pressure Catecholamine excess screen Plasma free metanephrines Twice yearly monitoring Two yearly monitoring Other monitoring
Annual monitoring
- History and physical examination
- Pulse and blood pressure
- Catecholamine excess screen
- Plasma free metanephrines
Twice yearly monitoring
Two yearly monitoring
Other monitoring
References
- Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer 2023 (Online ahead of print).
- Louise M Binderup M, Smerdel M, Borgwadt L, et al. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet 2022; 65:104538.
- Laks S, van Leeuwaarde R, Patel D, et al. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer 2022; 128:435-446.
